There's no doubt that there will be plenty of choices. The drug is known to work on over 100 different types of cancer. I think the point is to isolate the cancers that exhibit the strongest reaction to Coramsine and pursue those through phase II. This will give the best chance of a positive (and potentially dramatic) outcome.
- Forums
- ASX - By Stock
- SBP
- genentech up $11 billion
SBP
solbec pharmaceuticals limited
genentech up $11 billion, page-7
Add SBP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, Managing Director and CEO
Steven Gourlay
Managing Director and CEO
Previous Video
Next Video
SPONSORED BY The Market Online